Janux Therapeutics (JANX) Stock Forecast, Price Target & Predictions
JANX Stock Forecast
Janux Therapeutics stock forecast is as follows: an average price target of $59.25 (represents a 18.48% upside from JANX’s last price of $50.01) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
JANX Price Target
The average price target for Janux Therapeutics (JANX) is $59.25 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $70.00 to $42.00. This represents a potential 18.48% upside from JANX's last price of $50.01.
JANX Analyst Ratings
According to 3 Wall Street analysts, Janux Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for JANX stock is 0 'Strong Buy' (0.00%), 2 'Buy' (66.67%), 1 'Hold' (33.33%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Janux Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 05, 2024 | Bradley Canino | Stifel Nicolaus | $70.00 | $43.71 | 60.15% | 39.97% |
| Aug 09, 2024 | George Farmer | Scotiabank | $42.00 | $36.49 | 15.10% | -16.02% |
| May 30, 2024 | George Farmer | Scotiabank | $47.00 | $47.60 | -1.26% | -6.02% |
| May 13, 2024 | Swayampakula Ramakanth | H.C. Wainwright | $63.00 | $49.63 | 26.94% | 25.97% |
| Mar 20, 2024 | Kaveri Pohlman | BTIG | $62.00 | $39.13 | 58.45% | 23.98% |
The latest Janux Therapeutics stock forecast, released on Sep 05, 2024 by Bradley Canino from Stifel Nicolaus, set a price target of $70.00, which represents a 60.15% increase from the stock price at the time of the forecast ($43.71), and a 39.97% increase from JANX last price ($50.01).
Janux Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 2 | 5 |
| Avg Price Target | $70.00 | $56.00 | $56.80 |
| Last Closing Price | $50.01 | $50.01 | $50.01 |
| Upside/Downside | 39.97% | 11.98% | 13.58% |
In the current month, the average price target of Janux Therapeutics stock is $70.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 39.97% increase as opposed to Janux Therapeutics's last price of $50.01. This month's average price target is up 25.00% compared to last quarter, and up 23.24% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 06, 2024 | Scotiabank | Underperform | Underperform | Hold |
| Sep 06, 2024 | Wedbush | Sector Perform | Sector Perform | Hold |
| Aug 09, 2024 | Wedbush | Sector Perform | Sector Perform | Hold |
| Aug 09, 2024 | Scotiabank | Underperform | Underperform | Hold |
| Aug 09, 2024 | Scotiabank | Sector Perform | Sector Perform | Hold |
| May 30, 2024 | Wedbush | Sector Perform | Sector Perform | Hold |
| May 30, 2024 | Scotiabank | Underperform | Underperform | Hold |
| May 30, 2024 | Scotiabank | - | Sector Perform | Initialise |
| May 13, 2024 | Wedbush | Buy | Buy | Hold |
| May 13, 2024 | JonesTrading | Underperform | Underperform | Hold |
Janux Therapeutics's last stock rating was published by Scotiabank on Sep 06, 2024. The company gave JANX a "Underperform" rating, the same as its previous rate.
Janux Therapeutics Financial Forecast
Janux Therapeutics Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $2.52M | $1.06M | $2.05M | $2.85M | $1.81M | - | $1.59M | $1.62M | $1.16M | $482.00K |
| Avg Forecast | $15.07M | $14.30M | $13.56M | $12.87M | $166.67K | $166.67K | $166.67K | $166.67K | $710.00K | $760.00K | $772.00K | $878.57K | $750.00K | $845.50K | $875.00K | $672.35K | $805.50K | $742.58K | $650.00K | $810.40K | $433.33K | $133.33K | $133.33K |
| High Forecast | $15.07M | $14.30M | $13.56M | $12.87M | $166.67K | $166.67K | $166.67K | $166.67K | $710.00K | $760.00K | $772.00K | $878.57K | $811.22K | $845.50K | $875.00K | $672.35K | $805.50K | $742.58K | $650.00K | $909.63K | $486.39K | $149.66K | $149.66K |
| Low Forecast | $15.07M | $14.30M | $13.56M | $12.87M | $166.67K | $166.67K | $166.67K | $166.67K | $710.00K | $760.00K | $772.00K | $878.57K | $688.77K | $845.50K | $875.00K | $672.35K | $805.50K | $742.58K | $650.00K | $702.90K | $375.85K | $115.64K | $115.64K |
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | - | 1 | 2 | 2 | 2 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.98% | 1.21% | 3.05% | 3.53% | 2.44% | - | 1.96% | 3.73% | 8.69% | 3.62% |
Janux Therapeutics's average Quarter revenue forecast for Dec 23 based on 3 analysts is $750.00K, with a low forecast of $688.77K, and a high forecast of $811.22K. JANX's average Quarter revenue forecast represents a -70.20% decrease compared to the company's last Quarter revenue of $2.52M (Sep 23).
Janux Therapeutics EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | - | 1 | 2 | 2 | 2 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $-15.81M | $-20.75M | $-20.28M | $-18.27M | $-17.77M | - | $-13.46M | $-13.42M | $-10.74M | $-6.19M |
| Avg Forecast | $-3.01M | $-2.86M | $-2.71M | $-2.57M | $-33.33K | $-33.33K | $-33.33K | $-33.33K | $-142.00K | $-152.00K | $-154.40K | $-175.71K | $-150.00K | $-169.10K | $-175.00K | $-134.47K | $-161.10K | $-5.20M | $-130.00K | $-14.98M | $-86.67K | $-5.56M | $-17.65M |
| High Forecast | $-3.01M | $-2.86M | $-2.71M | $-2.57M | $-33.33K | $-33.33K | $-33.33K | $-33.33K | $-142.00K | $-152.00K | $-154.40K | $-175.71K | $-137.75K | $-169.10K | $-175.00K | $-134.47K | $-161.10K | $-4.16M | $-130.00K | $-11.98M | $-75.17K | $-4.45M | $-14.12M |
| Low Forecast | $-3.01M | $-2.86M | $-2.71M | $-2.57M | $-33.33K | $-33.33K | $-33.33K | $-33.33K | $-142.00K | $-152.00K | $-154.40K | $-175.71K | $-162.24K | $-169.10K | $-175.00K | $-134.47K | $-161.10K | $-6.24M | $-130.00K | $-17.98M | $-97.28K | $-6.67M | $-21.18M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 93.51% | 118.56% | 150.82% | 113.38% | 3.42% | - | 0.90% | 154.80% | 1.93% | 0.35% |
undefined analysts predict JANX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Janux Therapeutics's previous annual EBITDA (undefined) of $NaN.
Janux Therapeutics Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | - | 1 | 2 | 2 | 2 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $-11.57M | $-17.51M | $-14.18M | $-11.26M | $-14.04M | - | $-13.15M | $-13.34M | $-10.77M | $-6.21M |
| Avg Forecast | $-21.01M | $-18.11M | $-16.83M | $-15.72M | $-24.23M | $-23.31M | $-21.99M | $-20.83M | $-21.72M | $-18.83M | $-16.92M | $-18.04M | $-22.61M | $-25.59M | $-27.33M | $-26.46M | $-26.20M | $-5.21M | $-15.53M | $-15.22M | $-12.60M | $-5.57M | $-17.69M |
| High Forecast | $-21.01M | $-18.11M | $-16.83M | $-15.72M | $-24.23M | $-23.31M | $-21.99M | $-20.83M | $-21.72M | $-13.74M | $-16.92M | $-18.04M | $-18.33M | $-25.59M | $-27.33M | $-26.46M | $-26.20M | $-4.17M | $-15.53M | $-12.18M | $-10.43M | $-4.46M | $-14.15M |
| Low Forecast | $-21.01M | $-18.11M | $-16.83M | $-15.72M | $-24.23M | $-23.31M | $-21.99M | $-20.83M | $-21.72M | $-20.86M | $-16.92M | $-18.04M | $-25.66M | $-25.59M | $-27.33M | $-26.46M | $-26.20M | $-6.25M | $-15.53M | $-18.27M | $-14.61M | $-6.69M | $-21.22M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.45% | 0.64% | 0.54% | 0.43% | 2.70% | - | 0.86% | 1.06% | 1.93% | 0.35% |
Janux Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. JANX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Janux Therapeutics SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | - | 1 | 2 | 2 | 2 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $6.44M | $6.88M | $6.46M | $5.68M | $6.10M | - | $4.95M | $3.94M | $3.66M | $2.00M |
| Avg Forecast | $32.12M | $30.48M | $28.91M | $27.43M | $355.30K | $355.30K | $355.30K | $355.30K | $1.51M | $1.62M | $1.65M | $1.87M | $1.60M | $1.80M | $1.87M | $1.43M | $1.72M | $1.58M | $1.39M | $1.73M | $923.77K | $284.24K | $284.24K |
| High Forecast | $32.12M | $30.48M | $28.91M | $27.43M | $355.30K | $355.30K | $355.30K | $355.30K | $1.51M | $1.62M | $1.65M | $1.87M | $1.73M | $1.80M | $1.87M | $1.43M | $1.72M | $1.58M | $1.39M | $1.94M | $1.04M | $319.04K | $319.04K |
| Low Forecast | $32.12M | $30.48M | $28.91M | $27.43M | $355.30K | $355.30K | $355.30K | $355.30K | $1.51M | $1.62M | $1.65M | $1.87M | $1.47M | $1.80M | $1.87M | $1.43M | $1.72M | $1.58M | $1.39M | $1.50M | $801.23K | $246.53K | $246.53K |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.57% | 3.69% | 4.51% | 3.31% | 3.85% | - | 2.86% | 4.26% | 12.86% | 7.03% |
Janux Therapeutics's average Quarter SG&A projection for Dec 23 is $1.60M, based on 3 Wall Street analysts, with a range of $1.47M to $1.73M. The forecast indicates a -75.17% fall compared to JANX last annual SG&A of $6.44M (Sep 23).
Janux Therapeutics EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | - | 1 | 2 | 2 | 2 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.25 | $-0.42 | $-0.34 | $-0.27 | $-0.34 | - | $-0.32 | $-0.32 | $-0.26 | $-0.62 |
| Avg Forecast | $-0.39 | $-0.33 | $-0.31 | $-0.29 | $-0.44 | $-0.43 | $-0.40 | $-0.38 | $-0.40 | $-0.35 | $-0.31 | $-0.33 | $-0.42 | $-0.47 | $-0.50 | $-0.49 | $-0.48 | $-0.47 | $-0.32 | $-0.32 | $-0.27 | $-0.18 | $-0.14 |
| High Forecast | $-0.39 | $-0.33 | $-0.31 | $-0.29 | $-0.44 | $-0.43 | $-0.40 | $-0.38 | $-0.40 | $-0.25 | $-0.31 | $-0.33 | $-0.34 | $-0.47 | $-0.50 | $-0.49 | $-0.48 | $-0.47 | $-0.32 | $-0.26 | $-0.22 | $-0.15 | $-0.12 |
| Low Forecast | $-0.39 | $-0.33 | $-0.31 | $-0.29 | $-0.44 | $-0.43 | $-0.40 | $-0.38 | $-0.40 | $-0.38 | $-0.31 | $-0.33 | $-0.47 | $-0.47 | $-0.50 | $-0.49 | $-0.48 | $-0.47 | $-0.32 | $-0.37 | $-0.31 | $-0.20 | $-0.16 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.53% | 0.84% | 0.70% | 0.56% | 0.73% | - | 1.00% | 1.19% | 1.47% | 4.43% |
According to undefined Wall Street analysts, Janux Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to JANX previous annual EPS of $NaN (undefined).
Janux Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ANTX | AN2 Therapeutics | $1.04 | $8.75 | 741.35% | Buy |
| AVTE | Aerovate Therapeutics | $1.90 | $13.00 | 584.21% | Hold |
| MOLN | Molecular Partners | $5.22 | $29.00 | 455.56% | Buy |
| ANEB | Anebulo Pharmaceuticals | $2.08 | $6.00 | 188.46% | Buy |
| FENC | Fennec Pharmaceuticals | $5.47 | $15.75 | 187.93% | Buy |
| MLYS | Mineralys Therapeutics | $11.76 | $30.00 | 155.10% | Buy |
| EWTX | Edgewise Therapeutics | $18.83 | $48.00 | 154.91% | Buy |
| RZLT | Rezolute | $5.25 | $13.00 | 147.62% | Buy |
| ACRV | Acrivon Therapeutics | $8.91 | $21.50 | 141.30% | Buy |
| KROS | Keros Therapeutics | $56.98 | $105.00 | 84.28% | Buy |
| ELYM | Eliem Therapeutics | $8.46 | $13.00 | 53.66% | Buy |
| ADAG | Adagene | $3.49 | $5.00 | 43.27% | Buy |
| HRMY | Harmony Biosciences | $38.91 | $50.67 | 30.22% | Buy |
| JANX | Janux Therapeutics | $50.01 | $59.25 | 18.48% | Buy |
| CYT | Cyteir Therapeutics | $3.02 | $2.00 | -33.77% | Sell |
JANX Forecast FAQ
Is Janux Therapeutics a good buy?
Yes, according to 3 Wall Street analysts, Janux Therapeutics (JANX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 66.67% of JANX's total ratings.
What is JANX's price target?
Janux Therapeutics (JANX) average price target is $59.25 with a range of $42 to $70, implying a 18.48% from its last price of $50.01. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Janux Therapeutics stock go up soon?
According to Wall Street analysts' prediction for JANX stock, the company can go up by 18.48% (from the last price of $50.01 to the average price target of $59.25), up by 39.97% based on the highest stock price target, and down by -16.02% based on the lowest stock price target.
Can Janux Therapeutics stock reach $80?
JANX's average twelve months analyst stock price target of $59.25 does not support the claim that Janux Therapeutics can reach $80 in the near future.
What is Janux Therapeutics's current price target trend?
1 Wall Street analyst forecast a $70 price target for Janux Therapeutics (JANX) this month, up 39.97% from its last price of $50.01. Compared to the last 3 and 12 months, the average price target increased by 11.98% and increased by 13.58%, respectively.
What are Janux Therapeutics's analysts' financial forecasts?
Janux Therapeutics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $666.67K (high $666.67K, low $666.67K), average EBITDA is $-133K (high $-133K, low $-133K), average net income is $-90.368M (high $-90.368M, low $-90.368M), average SG&A $1.42M (high $1.42M, low $1.42M), and average EPS is $-1.66 (high $-1.66, low $-1.66). JANX's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $55.79M (high $55.79M, low $55.79M), average EBITDA is $-11.159M (high $-11.159M, low $-11.159M), average net income is $-71.667M (high $-71.667M, low $-71.667M), average SG&A $118.94M (high $118.94M, low $118.94M), and average EPS is $-1.316 (high $-1.316, low $-1.316).
Did the JANX's actual financial results beat the analysts' financial forecasts?
Based on Janux Therapeutics's last annual report (Dec 2023), the company's revenue was $8.08M, beating the average analysts forecast of $3.14M by 157.19%. Apple's EBITDA was $-72.979M, beating the average prediction of $-629K by 11510.40%. The company's net income was $-58.293M, missing the average estimation of $-102M by -42.85%. Apple's SG&A was $26.14M, beating the average forecast of $6.7M by 290.16%. Lastly, the company's EPS was $-0.0013, missing the average prediction of $-1.873 by -99.93%. In terms of the last quarterly report (Sep 2023), Janux Therapeutics's revenue was $2.52M, beating the average analysts' forecast of $845.5K by 197.69%. The company's EBITDA was $-15.813M, beating the average prediction of $-169K by 9251.33%. Janux Therapeutics's net income was $-11.568M, missing the average estimation of $-25.592M by -54.80%. The company's SG&A was $6.44M, beating the average forecast of $1.8M by 257.19%. Lastly, the company's EPS was $-0.25, missing the average prediction of $-0.47 by -46.81%